REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Oct 14, 2024
  • participants needed
    490
  • sponsor
    Relay Therapeutics, Inc.
Send
Updated on 14 September 2023
See if I qualify
measurable disease
growth factor
solid tumors
cancer chemotherapy
antineoplastic agents
antineoplastic
solid tumour
solid tumor
advanced solid tumor
FGFR2
growth factors
cholangiocarcinoma
intrahepatic bile duct carcinoma
immunostimulants
fgfr inhibitor

Summary

This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic cholangiocarcinoma (CCA) and other solid tumors. The study consists of 3 parts: a dose escalation (Part 1), a dose expansion (Part 2), and an extension (Part 3).

Details
Condition FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation, FGFR2 Gene Activation, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Other Solid Tumors, Adult
Treatment RLY-4008
Clinical Study IdentifierNCT04526106
SponsorRelay Therapeutics, Inc.
Last Modified on14 September 2023

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed unresectable or metastatic solid tumor
Documented FGFR2 gene fusion, mutation, or amplification per local testing of blood and/or tumor
Patient must have measurable disease per RECIST v1.1
Patient must have disease that is refractory to standard therapy, disease that has not adequately responded to standard therapy, disease for which standard or curative therapy does not exist, or the patient must be intolerant to or have declined standard therapy
Part 2 dose expansion patients with Cholangiocarcinoma
Group 1: CCA patients with an FGFR2 fusion previously treated with an FGFRi
Group 2: CCA patients with an FGFR2 fusion with prior chemotherapy but not previously treated with an FGFRi
Group 6: CCA patients with an FGFR2 fusion with no prior chemotherapy and not previously treated with an FGFRi. Prior adjuvant/neo-adjuvant treatment completed >6 months before enrollment is acceptable. Up to 2 cycles of palliative chemotherapy are allowed during screening
Group 7: CCA patients with an FGFR2 mutation or amplification and not previously treated with an FGFRi
Part 2 dose expansion patients with other solid tumors (NOT Cholangiocarcinoma)
Group 3: Non-CCA patients with an FGFR2 fusion and not previously treated with an FGFRi
Group 4: Non-CCA patients with an FGFR2 amplification and not previously treated with an FGFRi
Group 5: Non-CCA patients with an FGFR2 mutation and not previously treated with an FGFRi
Part 3 extension
Patient has ECOG performance status of 0-1
CCA patients with an FGFR2 fusion with prior chemotherapy but not previously treated with an FGFRi

Exclusion Criteria

Ongoing, clinically significant FGFRi-induced retinal detachment or an ongoing clinically significant corneal or retinal disorder
Patient does not have adequate organ function (defined in protocol)
Patient has active infection, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV) (defined in protocol). Patients with well-controlled HBV are eligible (defined in protocol)
QT interval corrected using Fridericia's formula (QTcF) > 480 msec or history of prolonged QT syndrome, Torsades de pointes or familial history of prolonged QT syndrome
Clinically significant, uncontrolled cardiovascular disease
CNS metastases or primary CNS tumor that is associated with progressive neurologic symptoms
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

measurable disease
growth factor
solid tumors
cancer chemotherapy
antineoplastic agents
antineoplastic
solid tumour
solid tumor
advanced solid tumor
FGFR2
growth factors
cholangiocarcinoma
intrahepatic bile duct carcinoma
immunostimulants
fgfr inhibitor

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note